1 results match your criteria: "Brazil. Electronic address: phillip.scheinberg@hospitalsjose.org.br.[Affiliation]"
Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.
Lancet Haematol
January 2016
Clinical Hematology, Antônio Ermírio de Moraes Cancer Center, Hospital São José and Beneficência Portuguesa, São Paulo, SP, Brazil. Electronic address:
Article Synopsis
- T-cell large granular lymphocytic leukaemia (T-LGL) is a blood cancer that often leads to immune-related blood cell deficiencies, and traditional treatments can be toxic over time.
- A study was conducted to evaluate the effectiveness and safety of alemtuzumab, an antibody treatment, in patients with T-LGL, involving a 10-day intravenous infusion and measuring blood response after 3 months.
- Out of 25 participants, 14 showed a positive response to the treatment, highlighting 74% effectiveness in those with classic T-LGL, though all patients experienced some infusion reactions.